Controlled trial of D-penicillamine with low dosis in the treatment of chronic liver diseases.
Controlled trial of D-penicillamine was carried out with low dosis in 10 patients with chronic persistent hepatitis, 11 patients with chronic aggressive hepatitis and 7 patients with liver cirrhosis. After 6 weeks and 6 months treatment mean values of transaminases improved in patients with chronic persistent hepatitis. The mean serum transaminases levels of the patients with chronic aggressive hepatitis were statistically decreased after 6 weeks treatment but not significantly lower after 6 months treatment than on entry. D-penicillamine is not effective for the treatment of patients with liver cirrhosis. Eight of 36 patients treated were withdrawn from the trial because of adverse drug toxicity side effects.
D000410:Alanine Transaminase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D001663:Bilirubin / Q000097:blood; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D006505:Hepatitis / Q000188:drug therapy*; D006801:Humans; D008103:Liver Cirrhosis / Q000188:drug therapy*; D008111:Liver Function Tests; D010396:Penicillamine / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D012709:Serum Albumin / Q000032:analysis; D012712:Serum Globulins / Q000032:analysis
D012709:Serum Albumin; D012712:Serum Globulins; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D010396:Penicillamine; D001663:Bilirubin